SENS's Quality Score fell 1 point on Tue, Nov 10, to 10. Its average daily range rose to 9.3%, with a $123M loss over four quarters and no positive free cash flow.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 26% from Nov 5 to Nov 10.
| The company | Sales up 105% on the year |
| Latest filing | 8-K, Nov 9 |
ReportLast night: sales of $19.6M; a loss of $0.50 a share. Raised its outlook for the year. Past reports ›
In the newsSenseonics delivers 'breakout quarter' more than doubling Eversense 365 revenue
Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +3.6% on average, higher 2 of 4 times.
Averagefor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. SENS scores 10 today, against a median of 2.5 over its last 20 recorded sessions.
SENS is #8 of 11 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 8 |
Expected to report Mon Mar 1, after the close (in 111 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $19.6M, 142% more than a year ago; a loss of $0.50 a share, from $0.43.
“Third quarter 2026 research and development expenses were $11.7 million, compared to $7.8 million for the third quarter of 2025, reflecting continued clinical trial activity for Gemini and development work on Freedom.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| United States | $16.8M | $12.6M | $6.4M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 9)
| Measure | Figure |
|---|---|
| Global net revenue | $68M to $70M |
Its share count grew 6.7% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | +27.0% | +2.4% | not yet |
| Aug 6, 2026 | +11.8% | +36.3% | +50.1% |
| May 7, 2026 | +0.2% | -6.2% | +8.6% |
Sales grew in six of the last seven years, to $35.3M in 2025. It made a profit in one of the eight years.
RSI 59.8, MACD above signal, above both averages. Not scored.
One insider bought $125K across 1 filing in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SENS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
“The market for CGM systems is developing and competitive, subject to rapid change and significantly affected by new product introductions.”
SENS scores 10 today, which Breakaway calls Average. It is #8 of 11 in Industrial Instruments for Measurement, Display, and Control by Quality Score, with 7 of 14 chart checks firing. Up 26% from Nov 5 to Nov 10. Shares: 46.2% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SENS scores 10 today, which Breakaway calls Average (6 to 10). That is #8 of 11 in Industrial Instruments for Measurement, Display, and Control by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SENS's 10.
One insider bought $125K across 1 filing in the last 6 months. No open-market sales on record. The newest is Douglas A. Roeder, Director, who bought $125K on Aug 19.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.